Search Results
Your search for ,sIX matches 2809 pages
Showing 1051 - 1100Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cambodia
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cambodia. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Mary-Claire King, PhD, Honored With 2020 William L. McGuire Memorial Lecture Award
Mary-Claire King, PhD, will receive the William L. McGuire Memorial Lecture Award at the 2020 San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8 to 12, 2020. The William L. McGuire Memorial Lectureship was established in 1992 to commemorate Dr. McGuire’s significant...
Rural Cancer Care: Models of Success and Barriers Highlighted in New State of Cancer Care in America Package
JCO Oncology Practice has published an article on rural cancer care as part of the State of Cancer Care in America series. “Closing the Rural Cancer Care Gap: Three Institutional Approaches” draws from data presented during the second State of Cancer Care in America live event as well as supporting ...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...
Heather Brandt, PhD, to Lead Cancer Prevention Community Outreach Projects for St. Jude
St. Jude Children’s Research Hospital has appointed Heather Brandt, PhD, a behavioral scientist with expertise in cancer prevention and control, to lead community outreach and research programs focused on the prevention of human papillomavirus (HPV)-associated cancers through vaccination. In...
Activity of Olaparib and Durvalumab in Germline BRCA-Mutated Metastatic Breast Cancer
As reported in The Lancet Oncology by Susan M. Domchek, MD, and colleagues, the combination of olaparib and durvalumab showed activity in a cohort of patients with germline BRCA-mutated, HER2-negative metastatic breast cancer enrolled in a phase I/II basket study (MEDIOLA). Study Details In the...
Early Rituximab Intensification in R-CHOP for Diffuse Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Pieternella Johanna Lugtenburg, MD, PhD, and colleagues, the phase III Haemato-Oncology Foundation for Adults in the Netherlands (HOVEN)/ Nordic Lymphoma Group HOVON-84 trial showed that early rituximab intensification in R-CHOP-14 (rituximab plus...
Study Finds Residents of Low-Income Neighborhoods Have Less Access to ICU Beds Amidst Coronavirus Pandemic
A new study published by Kanter et al in Health Affairs sheds light on another reason why the coronavirus pandemic is disproportionately affecting individuals of lower socioeconomic status: residents in low-income neighborhoods lack access to intensive care unit (ICU) beds. While the shortage of...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented during the ASCO20 Virtual Scientific Program by Elizabeth R....
Maintenance Avelumab Improves Survival in Advanced Bladder Cancer
Maintenance therapy with avelumab and best supportive care significantly prolonged overall survival vs best supportive care alone in patients with advanced urothelial carcinoma that did not progress on first-line platinum-based chemotherapy, according to an interim analysis of the phase III JAVELIN ...
Salvage Nivolumab Plus Ipilimumab After Prior Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Renal Cell Carcinoma
In a study reported in the Journal of Clinical Oncology,1 Anita Gul, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues found that salvage therapy with nivolumab/ipilimumab was capable of producing a response after prior PD-1 pathway inhibitor therapy in some patients with...
Enzalutamide Improves Survival vs Standard First-LineTreatment in Hormone-Sensitive Metastatic Prostate Cancer
As reported inThe New England Journal of Medicine by Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of Monash University and Eastern Health in Melbourne, and colleagues, the phase III ENZAMET trial has shown that the androgen receptor inhibitor enzalutamide improved progression-free and overall survival...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented during the ASCO20 Virtual Scientific Program1 and published as a brief report in JAMA Oncology,2 Praful Ravi, MB, BChir, of the Dana-Farber Cancer Institute, Boston, and colleagues found that rechallenge with immune checkpoint inhibitor therapy was capable of producing...
Pembrolizumab Monotherapy as First-Line Treatment for Patients With Unresectable Cutaneous Squamous Cell Carcinoma
In the French phase II CARSKIN trial reported in the Journal of Clinical Oncology, Maubec et al found that pembrolizumab monotherapy produced durable responses in the first-line treatment of unresectable cutaneous squamous cell carcinoma. Study Details In the multicenter trial, 39 patients (primary ...
Fixed-Dose Subcutaneous Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf in HER2-Positive Breast Cancer
On June 29, 2020, a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) for subcutaneous injection was approved for the following indications1,2: Use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced,...
Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient
Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...
Lost in Translation: A Fisherman’s Tale
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
National Comprehensive Cancer Network Celebrates Its 25th Year
It was February 1996, and the first annual meeting of the National Comprehensive Cancer Network® (NCCN®) was drawing to a close, when Chief Executive Officer (CEO) Bruce R. Ross, MD, invited comments from the floor. An oncologist who had attended at the urging of a friend—somewhat reluctantly—stood ...
Multiple Lesions Not a Contraindication for Cosmetically Acceptable Lumpectomy
More than 70% of women with multiple tumors in a single breast reported good or excellent satisfaction with the cosmetic results of breast-conserving therapy, Alliance (ACOSOG) Z11102 investigators reported at the 2020 American Society of Breast Surgeons (ASBrS) Virtual Scientific Session.1 In...
First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...
Overcoming the Challenges of Improving Psychosocial Care for Patients With Cancer
Although the United States spends billions of dollars each year on cancer research, very little of that funding is dedicated to mental health research in patients with cancer, despite the fact that cancer survivors have a six-time higher risk for psychological disability than people without...
Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial has shown that treatment with pembrolizumab resulted in durable responses in patients with recurrent or metastatic cutaneous squamous cell carcinoma. The study supported the...
Outcomes With PET-Directed Therapy for Limited-Stage DLBCL
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in patients with limited-stage diffuse large B-cell lymphoma ...
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
According to research published by Russell et al in Frontiers in Oncology, patients with a longer-established diagnosis of cancer are at increased risk for more severe infection with COVID-19, as well as death from the virus. Patients of Asian ethnicity or who were receiving palliative treatment...
Weathering the Storm: Personal Steps Toward Racial Equity in Oncology
“Of all the forms of inequality, injustice in health is the most shocking and the most inhumane because it often results in physical death. I see no alternative to direct action and creative nonviolence to raise the conscience of the nation.” —Martin Luther King, Jr, speaking before the Medical...
The Wake
The ASCO Post is pleased to reproduce installments of the “Art of Oncology,” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
Addition of Rituximab to Standard Chemotherapy Improves Event-Free and Overall Survival in Children With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Véronique Minard‑Colin, MD, PhD, of Gustave Roussy, Université Paris-Saclay, Villejuif, France, and colleagues found that the addition of rituximab...
When Paired With Palbociclib, Fulvestrant and Letrozole Yield Comparable Results in PARSIFAL Trial
When paired with palbociclib in the first-line treatment of metastatic breast cancer, fulvestrant and letrozole performed comparably, with no statistical superiority in progression-free or overall survival shown for either endocrine agent, in the phase II PARSIFAL study presented during the ASCO20...
Effect of Breast Cancer Pathway Implementation on Rate of Referrals for Genetic Counseling and Testing
In a study reported in JCO Oncology Practice, Stephanie L. Graff, MD, and colleagues found that patients with breast cancer seen by a physician with training in using an established pathway for genetic counseling and testing referral were more frequently referred for such services vs patients seen...
In Keynote Lecture, Anthony Fauci, MD, Explores What We Know About COVID-19 and What’s Being Done to Combat It
Kicking off the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer earlier this week, Anthony Fauci, MD, gave the keynote lecture, “Coronavirus Infections: More Than Just the Common Cold.” As Dr. Fauci told listeners, “[COVID-19]—and other infectious...
Eric Zhou, PhD, on Insomnia in Young Cancer Survivors: Online Program May Improve Quality of Life
Eric Zhou, PhD, of Dana-Farber Cancer Institute, discusses an existing online program called SHUTi (Sleep Healthy Using the Internet), that he and his team adapted to the needs of adolescent and young adult cancer survivors. After six online cognitive behavior therapy sessions delivered over 8...
Potential Association of Impaired Spermatogenesis and Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Melanoma
In a study reported as a research letter in JAMA Oncology, Scovell et al identified a potential association between the use of immune checkpoint inhibitors and impaired spermatogenesis using autopsy tissue findings in men with a history of metastatic melanoma. Study Details The study involved...
Expect Questions About Minimally Invasive Surgery for Early-Stage Cervical Cancer
A recent systematic review and meta-analysis found that women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of disease recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy.1 “These...
Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
Atezolizumab as First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression and No EGFR or ALK Aberrations
On May 18, 2020, atezolizumab was approved for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. High PD-L1 expression is defined as PD-L1 staining of at least 50% of...
Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Proves Active in Refractory Metastatic Melanoma
Patients with heavily pretreated metastatic melanoma treated with adoptive cell therapy based on tumor-infiltrating lymphocytes achieved a response rate of 36%, a disease control rate of 80%, and a median duration of response that had not been reached by 18 months in the global open-label phase II...
Two Studies Validate Neoadjuvant Chemotherapy With Short-Course Radiotherapy or Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer
In the treatment of resectable, locally advanced rectal cancer, researchers are trying to identify the most effective chemotherapy regimens, the best radiotherapy approaches, and the optimal sequence of these modalities. Two phase III trials presented during the ASCO20 Virtual Scientific Program...
Roundup of High-Impact Studies in Early Breast Cancer
Clinicians interested in breast cancer who logged into the ASCO20 Virtual Scientific Program were greeted with an abundance of high-impact presentations. The ASCO Post has reported on several studies in depth elsewhere, but here we offer our readers a roundup of several important studies in early...
Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma
Data from the phase II PrE0505 multicenter trial showed that adding durvalumab, an immune checkpoint antibody targeting programmed cell death ligand 1 (PD-L1), to the combination of cisplatin and pemetrexed chemotherapy improved outcomes in previously untreated patients with unresectable malignant...
Her Grandfather’s Medical Practice Inspired Nathalie LeVasseur, MD, BSc, FRCPC, to Improve the Lives of Women With Breast Cancer
At the 2018 ASCO Annual Meeting, Nathalie LeVasseur, MD, BSc, FRCPC, received the Annual Meeting Merit Award for a project titled, “Whole-Genome Sequencing in Metastatic Breast Cancer: Lessons Learned From the BC Cancer Personalized Oncogenomics Program.” Along with her clinical work, Dr....
Improving the Quality of Care and Research for Patients With Cancer and the Ethics Behind Its Delivery
With the rapid expansion of scientific advances, the intersection of ethics and the delivery of cancer care becomes ever more complicated. To shed light on some of the challenging ethical issues faced by today’s busy oncology practitioners, The ASCO Post spoke with Rebecca D. Pentz, PhD, Professor ...
Insomnia in Adolescent and Young Adult Cancer Survivors
Adolescents and young adults (AYA) who have survived cancer may continue to suffer from insomnia long after treatment ends, interfering with a range of daily activities. In Pediatric Blood & Cancer, Eric S. Zhou, PhD, and Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute,...
Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma
Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Fader et al in Clinical Cancer Research. Each year, more than 65,650 women in the United States...
Advanced Bladder Cancer Survival Improved With Maintenance Avelumab
According to an interim analysis of the phase III JAVELIN Bladder 100 trial, rates of survival among patients with advanced urothelial carcinoma who did not progress on first-line platinum-based chemotherapy were significantly prolonged by maintenance therapy with avelumab and best supportive care...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
FDA Pipeline: Agents for the Treatment of Prostate and Pancreatic Cancers, Marginal Zone Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack,...
